Amylyx Pharmaceuticals, Inc.
AMLX
$32.40
-$1.48-4.37%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -43.42M | -41.28M | -33.00M | -34.39M | -41.44M |
| Total Depreciation and Amortization | 43.00K | 98.00K | 108.00K | 120.00K | 141.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.13M | 9.56M | 4.90M | 5.83M | 6.09M |
| Change in Net Operating Assets | 4.82M | -5.26M | 92.00K | -1.94M | 9.96M |
| Cash from Operations | -31.42M | -36.88M | -27.90M | -30.37M | -25.25M |
| Capital Expenditure | -30.00K | -- | -86.00K | -24.00K | -17.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -149.77M | 36.26M | 29.55M | 5.26M | 23.01M |
| Cash from Investing | -149.80M | 36.26M | 29.47M | 5.24M | 22.99M |
| Total Debt Issued | -- | -- | -375.00K | 191.11M | 0.00 |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.97M | 7.16M | 376.00K | 2.66M | 72.00K |
| Repurchase of Common Stock | -494.00K | -3.94M | -209.00K | -2.16M | -103.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1.48M | 3.22M | -208.00K | 191.61M | -31.00K |
| Foreign Exchange rate Adjustments | -68.00K | -111.00K | 118.00K | 151.00K | 608.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -179.81M | 2.49M | 1.48M | 166.63M | -1.68M |